Ex vivo lung perfusion: initial Brazilian experience.
In the last 20 years, lung transplantation has become the standard treatment for patients with end-stage lung disease. However, less than 20% of the donor lungs available for transplant are actually usable. This disparity between the growing number of recipients and the small number of donors has resulted in increased mortality among lung transplant candidates on waiting lists. Strategies such as the utilization of organs from marginal donors have proven ineffective in increasing the number of transplants. In 2000, a new method for reconditioning human lungs that had been previously rejected for transplantation was developed in Sweden. We describe our initial experience with ex vivo lung perfusion.
Pêgo-Fernandes
Paulo Manuel
PM
Department of Thoracic Surgery, University of São Paulo School of Medicine, São Paulo, Brazil. paulopego@incor.usp.br
Medeiros
Israel Lopes de
IL
Mariani
Alessandro Wasum
AW
Fernandes
Flávio Guimarães
FG
Unterpertinger
Fernando do Valle
Fdo V
Samano
Marcos Naoyuki
MN
Werebe
Eduardo de Campos
Ede C
Jatene
Fábio Biscegli
FB
D000368:Aged; D001938:Brazil; D046148:Donor Selection; D006801:Humans; D008168:Lung; D016040:Lung Transplantation; D008875:Middle Aged; D009926:Organ Preservation / Q000379:methods*; D010477:Perfusion / Q000295:instrumentation / Q000379:methods*